Does PCOS Go Away After Menopause?

PCOS and menopause both involve major hormone shifts, but one does not cancel out the other. PCOS, renamed PMOS in 2026, does not disappear at menopause. Ovulation-related symptoms often ease, but weight gain, insulin resistance, and long-term metabolic risk usually persist, and GLP-1 medications remain one option for managing that weight through the transition.

Key takeaways

• PCOS was renamed PMOS (polyendocrine metabolic ovarian syndrome) in a May 2026 global consensus. Diagnosis and day-to-day management have not changed.
• PCOS and menopause overlap heavily in symptoms, but PCOS does not go away. Weight gain and insulin resistance tend to be the most persistent symptoms into midlife.
• A large 2026 population study found women with PCOS may reach menopause later and report fewer classic menopause symptoms than women without PCOS.
• A 2024 Neurology study found measurably lower cognition scores in women with PCOS at midlife, a newer research area most guides on this topic still skip entirely.
• A peer-reviewed meta-analysis of randomized trials found tirzepatide and semaglutide produce meaningful weight loss specifically in women with PCOS and obesity, though neither is FDA-approved to treat PCOS itself.

At a glance

What’s in this guide

• Part 1: Understanding PCOS and menopause together, including the 2026 name change and the four life stages
• Part 2: Why weight and metabolism change after 40, and where GLP-1 treatment fits in
• Part 3: Long-term health, a screening checklist, and red flags
• Part 4: 12 frequently asked questions, answered directly

Part 1: Understanding PCOS and Menopause Together

PCOS Was Renamed PMOS in 2026. Does That Change Anything for You?

If you searched for PCOS and menopause and noticed a new term, you are not imagining it. In May 2026, a global consensus process published in The Lancet renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome, or PMOS.

The change involved more than 56 patient and clinical organizations and drew on survey responses from over 14,000 people with the condition and health professionals worldwide. The Endocrine Society backed the new name specifically because it reflects hormone and metabolic effects across the whole body, not just the ovaries.

Nothing about your diagnosis, symptoms, or treatment plan changes because of the new name. Rollout across clinical guidelines and insurance coding is expected to take about three years. Because almost everyone searching for information right now still uses “PCOS,” this guide leads with that term throughout and notes PMOS where relevant.

The Four Stages: How PCOS Shows Up From Your 30s Through Postmenopause

PCOS does not switch off at any single point. It moves through the same four stages every woman moves through, with its own pattern layered on top, since PCOS and menopause timelines run side by side rather than one replacing the other.

Does PCOS delay menopause?

Research points toward yes, though estimates vary by study. A large 2026 population-based cohort study, drawn from a Finnish birth cohort of over 1,800 women, found that women with PCOS were significantly less likely to have reached late perimenopause or postmenopause by age 46 than women without PCOS, and reported meaningfully fewer hot flashes and sleep disturbances at that age. Earlier, smaller studies estimated the delay at one to four years. None of this means PCOS protects you from menopause. It means the timeline tends to shift later, and the symptom experience may look somewhat different.

PCOS vs. Perimenopause Symptoms: What Overlaps and What Is Different

PCOS and perimenopause share enough symptoms that a new diagnosis in your 40s can get missed, chalked up to “just perimenopause” when PCOS was there all along, sometimes for decades undiagnosed. The table below breaks down where the two overlap and where they diverge.

Weight gain and sleep problems sit in both columns, which is exactly why they are the hardest symptoms to trace to a single cause. If you already have a PCOS diagnosis and new symptoms show up in your 40s, both explanations are worth raising with your provider rather than assuming one and ruling out the other.

Part 2: Why Weight and Metabolism Change After 40

Why Weight Gain Gets Harder to Manage With PCOS After 40

Two separate mechanisms stack on top of each other here, which is why “just eat less, move more” tends to stop working as well after 40 for women with PCOS.

The first is PCOS itself. Insulin resistance is central to the condition for most women who have it, meaning cells respond less efficiently to insulin, blood sugar runs higher, and the body compensates by producing more insulin, which drives more androgen production and more fat storage.

The second is the menopause transition. As estrogen declines, fat tends to redistribute toward the midsection rather than the hips and thighs, and resting metabolic rate drops as lean muscle mass naturally decreases with age. Clinicians sometimes describe this as a double hit for women with PCOS: insulin resistance that was already present, layered under a hormonal shift that independently favors abdominal weight gain. PCOS and menopause are two physiological processes working against each other at the same time, not a motivation problem.

Can Semaglutide or Tirzepatide Help With PCOS-Related Weight Gain During Perimenopause and Menopause?

Semaglutide and tirzepatide are GLP-1 receptor agonists. They slow stomach emptying, increase fullness after meals, and help regulate blood sugar, mechanisms that overlap directly with the insulin resistance driving weight gain in PCOS.

What the research specifically on PCOS shows

A peer-reviewed meta-analysis of four randomized controlled trials, covering 176 women diagnosed with PCOS by the Rotterdam criteria, compared GLP-1 receptor agonists against placebo for weight and hormonal markers.

The same body of research links GLP-1 treatment to improvements in testosterone levels and markers of insulin resistance in women with PCOS, on top of the weight change. A separate academic review specifically evaluating tirzepatide for PCOS management noted the benefit applies mainly to women who are also living with obesity or metabolic syndrome, and may not apply to women with PCOS at a normal weight.

Real-world prescribing reflects this shift. Health data firm Truveta, working with Reuters, found that semaglutide or tirzepatide prescribing among patients with a PCOS diagnosis rose from 2.4% in 2021 to 17.6% in 2025, more than a seven-fold increase.

That distinction matters for how you think about treatment. A provider is not prescribing semaglutide or tirzepatide to cure PCOS. They are evaluating whether weight management support is appropriate for you individually, and PCOS-driven insulin resistance is one factor that evaluation can reasonably take into account.

This is also where AHC differs from a general nutrition or supplement approach. AHC providers prescribe compounded semaglutide and compounded tirzepatide only after an individual evaluation by a licensed U.S. clinician, filled through a licensed 503A pharmacy. Compounding rules for GLP-1 medications changed significantly through 2025 and 2026, so any compounded prescription now requires a documented, patient-specific clinical reason, not simply a preference for lower cost.

AHC offers compounded semaglutide and compounded tirzepatide at flat monthly pricing with no dose-escalation markups. Eligibility depends on an individual evaluation, not a PCOS diagnosis alone.

If PCOS, perimenopause, or both are behind your current weight, a free evaluation is the fastest way to get an individualized answer instead of guessing from symptoms alone.

Part 3: Long-Term Health, Screening, and Red Flags

Long-Term Health Risks Worth Knowing About

PCOS and menopause together raise a few specific long-term risks worth tracking even when day-to-day symptoms feel manageable. None of these are guaranteed outcomes. They are reasons for regular screening, not a diagnosis in themselves.

• Type 2 diabetes and prediabetes, driven by the insulin resistance already central to PCOS.
• Cardiovascular risk factors, including higher blood pressure and unfavorable cholesterol patterns.
• Endometrial cancer risk, tied to years of irregular ovulation and unopposed estrogen exposure if cycles were not medically managed earlier in life.
• Continued androgen-related symptoms, such as facial hair growth or scalp thinning, which can persist independent of metabolic risk.

A newer research area: PCOS and brain health at midlife

Most guides on this topic stop at metabolic and cardiovascular risk. A 2024 study in Neurology, the journal of the American Academy of Neurology, adds a newer finding worth knowing about. Researchers followed participants for decades as part of the CARDIA cohort and found that at midlife, women with PCOS scored about 11% lower on tests of attention, verbal learning, and memory than women without PCOS, alongside more structural changes in the brain’s white matter.

The lead author, Dr. Heather Huddleston of UCSF, and other researchers were careful to frame this as an association, not proof that PCOS causes cognitive decline, since the study was observational. A researcher not involved in the study, Dr. Pauline Maki of the University of Illinois Chicago, added an important clarification: these are cognitive weaknesses, not impairments. The practical takeaway echoed by the study authors is that managing cardiovascular and metabolic risk factors, including regular exercise, may support brain health alongside everything else PCOS already asks you to manage.

A Screening Checklist for PCOS After 40

Bring this PCOS and menopause screening checklist to your next appointment, whether that is with your gynecologist, primary care provider, or an AHC clinician during your evaluation.

1. A1C or fasting glucose, to screen for insulin resistance and prediabetes.

2. A lipid panel, to check cholesterol and triglycerides.

3. Blood pressure check, at every visit from your 40s onward.

4. Thyroid function testing, since thyroid conditions can mimic or compound PCOS symptoms.

5. Liver function tests, given the metabolic overlap between PCOS and fatty liver risk.

6. Evaluation of any abnormal uterine bleeding, particularly if you go more than three months without a period and are not yet in confirmed menopause.

None of this requires waiting for symptoms to become severe. Annual screening is the more useful habit, especially once PCOS and perimenopause start overlapping.

When to See a Doctor Right Away

Most PCOS and menopause symptoms are uncomfortable, not urgent. A short list is the exception and deserves prompt medical attention rather than a wait-and-see approach:

• Very heavy bleeding, or bleeding that soaks through a pad or tampon every hour.
• Any bleeding after twelve consecutive months without a period.
• Severe or sudden pelvic pain.
• Chest pain or shortness of breath.

Part 4: Frequently Asked Questions About PCOS and Menopause

Is PCOS now called PMOS?

Yes. In May 2026, a global consensus published in The Lancet renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, or PMOS. The diagnosis and its management are unchanged. Rollout across guidelines and insurance systems is expected to take about three years, so whether you are researching PCOS and menopause together or PCOS on its own, you will likely see both terms used for a while.

Does PCOS go away after menopause?

No. PCOS does not go away after menopause. Ovulation-related symptoms like irregular periods stop being relevant once periods stop for good, but the underlying insulin resistance and androgen-related effects typically continue.

Do women with PCOS go through menopause earlier or later than average?

Research points toward later, though findings vary by study. A large 2026 population-based cohort study found women with PCOS were significantly less likely to have reached late perimenopause or postmenopause by age 46 than women without PCOS, and reported fewer hot flashes and sleep disturbances at that age. Earlier smaller studies have estimated the delay at one to four years.

Can you be newly diagnosed with PCOS during perimenopause?

Yes. Because PCOS and perimenopause share symptoms like irregular cycles and weight gain, some women are not diagnosed until their 40s, when a provider investigates persistent symptoms that perimenopause alone does not fully explain.

Why does weight loss get harder with PCOS after 40?

Insulin resistance from PCOS and the metabolic slowdown that comes with declining estrogen both push in the same direction: more fat storage, particularly around the midsection, and a lower resting metabolic rate. The two effects compound each other rather than simply adding up.

Can semaglutide or tirzepatide help with PCOS weight gain after 40?

They are not approved to treat PCOS directly. A meta-analysis of randomized trials in women with PCOS found meaningful weight loss with tirzepatide and semaglutide compared with placebo, with the strongest evidence in women who also have obesity. For women whose weight gain is driven partly by PCOS-related insulin resistance, addressing weight through this medication class, after an individual evaluation, may help with weight-related symptoms as a secondary effect.

Does PCOS affect brain health or memory at midlife?

A 2024 study in Neurology found women with PCOS scored about 11% lower on attention, verbal learning, and memory tests at midlife, with more white matter changes on brain imaging. The study was observational and the researchers describe the effect as a cognitive weakness, not an impairment. It is an active area of new research, not a settled risk.

What blood tests should you ask your provider about if you have PCOS and are approaching menopause?

A1C or fasting glucose, a lipid panel, blood pressure, thyroid function, liver function, and evaluation of any abnormal bleeding are the standard screening set worth asking about at least annually.

Does PCOS increase cancer risk after menopause?

PCOS is associated with a higher lifetime risk of endometrial cancer, linked to years of irregular ovulation and unopposed estrogen exposure if cycles were not medically managed. This is a risk factor to discuss with your provider, not a guaranteed outcome.

Do PCOS symptoms like acne and excess hair growth improve or worsen after menopause?

It varies. Some women see mild improvement as androgen levels gradually decline with age, while others continue to notice facial hair growth or scalp thinning well into postmenopause, since these symptoms do not track perfectly with reproductive hormone changes.

Is hormone replacement therapy safe if you have PCOS?

It can be an option for managing menopausal symptoms, but the decision depends on your individual health history, including cardiovascular and metabolic risk factors already elevated by PCOS. This is a conversation for your provider, not a one-size-fits-all answer.

Does AHC compounded semaglutide or tirzepatide treatment require a PCOS diagnosis?

No. Eligibility is based on an individual evaluation with a licensed provider, not a specific diagnosis. A PCOS history is simply one relevant factor that evaluation can take into account.

Find out what is actually driving your weight gain before guessing at a fix.

Find Out What Is Actually Driving Your Weight Gain

PCOS and menopause, or both together, can make weight gain feel impossible to reason with. A free evaluation with a licensed AHC provider looks at your individual history, not just a symptom checklist, to find out whether a weight management plan built around compounded semaglutide or compounded tirzepatide makes sense for you.

Start your free evaluation – Click Here

Free AHC calculators and tools

BMI calculator

GLP-1 weight loss projection calculator

See all AHC weight loss calculators

Related reading

Semaglutide for PCOS

Perimenopause weight gain and GLP-1 treatment

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with questions about a medical condition. Semaglutide and tirzepatide are prescription medications available only after an individual evaluation by a licensed provider. Results vary by individual, and AHC makes no guarantee of specific weight loss outcomes. Provider and compliance review is required before this article is published, given the eligibility, weight-management, and regulatory content it contains.